Ripley94
10 Mar 2017
Re: 9.5% rise... Very quite board .No mention of placing @ 35p 21/10/2016. 1 mil raiseAnother RNS today further placing @ 52p. 2m to 5m raise.
Ripley94
09 Mar 2017
Re: 9.5% rise... N/C.19/09/12. ( 53 )24/10/12.
Chrissp
17 Feb 2017
Price Movement What is going on here? Huge volume traded today and price rocketing early to 70 P.Looks like something big is going on and it has leaked out.
Nice to Michu
26 Jan 2017
I have high hopes here and having bought small in 30's and 40's p I am continuing to build a position out slowly here. I'm very comfortable buying in 50's, not least because I'm well up on current position but also because I see 80p as a realistic target in coming months and much more if this drug gets final approval.But its a one trick pony type stock and so if poor results from phase III testing then huge ouch.. but side effects seem not to be an issue and so I see plenty of time/room for this to appreciate in 2017 ahead of Jan 2018 detailed testing results.
Sambram
07 Sep 2016
Lupuzor update "ImmuPharma has announced that it has been invited to open an additional site in Mauritius as part of its Phase III clinical trial of Lupuzor™, its lead programme for the treatment of auto-immune disease Lupus. Up to 30 lupus patients are reportedly ready for enrolment – these will comprise part of the original 200 patients expected to be recruited for the Phase III trial – in a country where the relative incidence of the disease is high. Today’s news further illustrates, in our view, the continued lack of affordable and effective treatments for the disease, reflecting demand which is global in nature."Panmure note on research tree
rpg7
11 Aug 2016
Re: SP ACTION Tail wagging the dog again!
Simbr
14 Jun 2016
Re: Lupuzor trial steps up Two notes out this morning (both on research tree)
anmure:"Last week, ImmuPharma hosted a symposium featuring Prof Sylviane Muller, the inventor of Lupuzor, detailing the discovery, mechanism of action and wider opportunity for the use of Lupuzor in the treatment of Lupus and a variety of other autoimmune indications. A presentation from the event can be viewed online and offers investors a chance to look further into the detail of the molecule which, while by no means ImmuPharma’s only development programme, is clearly the most important near-term value driver for the business."and Northland:"Last week we attended a symposium hosted by ImmuPharma on LupuzorTM, the company's lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. The event was led by Prof. Sylviane Muller, the inventor of LupuzorTM, who presented on the unique mechanisms of action of the drug. Prof. Muller recently received 'The CNRS Medal of Innovation' for her discoveries made on LupuzorTM. The symposium provided a good overview of the mechanisms of action of LupuzorTM. Also of particular interest, was the evidence provided on the further potential uses of the drug in other major disease indications, including Rheumatoid Arthritis, Crohn’s Disease, and Asthma."
Simbrad
07 Jun 2016
Northland also published a note..."ImmuPharma issued an update on the progress of its Phase 3 clinical trial of LupuzorTM, its lead programme for the potential treatment of Lupus. The company confirmed that the first European sites have now commenced dosing Lupus patients. Recruitment in the study will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe. ImmuPharma’s lead programme is progressing to plan, with patients now being dosed in Europe and America. The Phase 3 clinical trial is expected to deliver a read-out by the end of 2017." pulled from Research Tree
Simbr
07 Jun 2016
Re: Lupuzor trial steps up Northland also published a note..."ImmuPharma issued an update on the progress of its Phase 3 clinical trial of LupuzorTM, its lead programme for the potential treatment of Lupus. The company confirmed that the first European sites have now commenced dosing Lupus patients. Recruitment in the study will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe. ImmuPharma’s lead programme is progressing to plan, with patients now being dosed in Europe and America. The Phase 3 clinical trial is expected to deliver a read-out by the end of 2017." (taken from Research Tree)
Simbr
07 Jun 2016
Lupuzor trial steps up Panmure published a note this morning on Research Tree: "This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal Phase III clinical study for Lupuzor™. This means that both US and European sites are now dosing patients in the Phase III trial (recruitment is expected in up to 45 investigator sites) and with Lupus continuing to represent a major unmet medical need we consider the ongoing demand for an effective treatment – highlighted by still torpid sales of GSK’s Benlysta – represents a major opportunity for ImmuPhara."
Simbrad
07 Jun 2016
Panmure published a note this morning on Research Tree: "This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal Phase III clinical study for Lupuzor™. This means that both US and European sites are now dosing patients in the Phase III trial (recruitment is expected in up to 45 investigator sites) and with Lupus continuing to represent a major unmet medical need we consider the ongoing demand for an effective treatment – highlighted by still torpid sales of GSK’s Benlysta – represents a major opportunity for ImmuPhara."
rpg7
03 Jun 2016
SP ACTION Look at the share trades this am -a lesson in how to decimate a share price with half a dozen controlled sells .
Simbrad
26 May 2016
Northland Capital Partners published a note on Immupharma this morning, it's out on Research Tree: "Alto’s investment further corroborates our view that ImmuPharma represents a good investment opportunity. The group’s lead drug, a potential treatment for Lupus, currently in a Phase 3 clinical trial, is expected to deliver a pivotal read-out by the end of 2017..."
vermilion100
02 Dec 2015
Re: The best ever buying opportunity... Probably, for some of us who invested in 2007 and seen forecast after forecast missed. All the more galling that one time IMM appeared 6 months behind the main competitor. Now we see a weekly sell off even with positive news; that does beggar the question; does someone know something we don't?
rpg7
01 Dec 2015
Re: sp action Still the travesty continues -5% down on £8000 worth of sales- in any other walk of life such things would be classed as fraud
